Direvo Reaches Milestone in Consolidated Bioprocessing of Lignocellulose to Lactic Acid
News Mar 12, 2013
Direvo Industrial Biotechnology GmbH (Direvo) has announced that it has reached an important milestone in developing a consolidated bioprocess for lactic acid production from lignocellulose.
Up until now, there has not been any known consolidated bioprocess for producing lactic acid from lignocellulose.
Direvo has now successfully built up a processing chain from pretreatment through fermentation to downstream processing for a consolidated bioprocess for lactic acid.
On the basis of pretreated Miscanthus grass, Direvo fermented lactic acid on pilot scale in a single-step-synthesis.
Direvo was further able to show that the important step of downstream processing of free lactic acid in the fermentation matrix can be realized efficiently by standardized procedures.
The downstream processing was executed in collaboration with the department of bioengineering of the Leibniz Institute for Agricultural Engineering Potsdam-Bornim.
Direvo’s specific, self-isolated proprietary microorganism Caldicellulosiruptor sp. produces the needed enzymes to ferment the pretreated biomass and converts the emerging sugar to end products.
In these processes, no cost-intensive technical enzymes have to be added.
A further advantage is that these microorganisms are extreme thermophile and therefore high process temperatures don’t cause product losses through contamination with foreign bacteria.
On the basis of this proof-of-concept, the next development stage to raise competitiveness in a commercial environment will be to increase the yield of lactic acid.
Consolidated bioprocessing is the conversion of lignocellulose into target products in a single step without having to add enzymes.
Direvo develops consolidated bioprocesses for production of biofuels and biobased chemicals under the brand name BluCon®.
Beside Lactic Acid, BluCon®-L, Direvo pursues with Ethanol, BluCon®-E, another product line.
BluCon® converts various non-food biomass ranging from grasses and straw to agricultural and wood residues and can therefore be applied around the globe.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019